评估国产SR-ENS-600单孔腹腔镜手术机器人系统联合加速康复外科(enhance recovery after surgery, ERAS)方案治疗卵巢囊肿、子宫肌瘤、宫颈上皮内瘤变等妇科良性疾病的临床疗效与安全性。

采用单臂研究设计，纳入2023年1月至2025年10月在北京协和医院妇产科接受手术的44例妇科良性疾病患者。所有患者均通过SR-ENS-600系统完成单孔腹腔镜手术，并实施标准化ERAS围术期管理。记录手术成功率、围术期关键指标(手术时间、术中出血量、肛门排气时间、术后住院时间)、疼痛数字等级评定量表(numerical rating scale，NRS)评分及不良事件发生情况，并与文献报道的达芬奇SP系统数据进行对比分析。

手术成功率100%，无中转开腹或多孔腹腔镜。其中卵巢囊肿剔除/附件切除术(SRC)组、子宫肌瘤剔除术(SRM)组及全部患者的手术时间、术中出血量均低于文献报道的达芬奇SP系统对应术式；全子宫切除术(SRH)组手术时间及出血量略高于达芬奇SP系统，但差异无统计学意义。全组患者术后肛门排气时间为20.97±6.23 h，术后住院时间为2.86±1.66 d，均显著短于达芬奇SP系统(分别为34.1±15.5 h、4.6±0.7 d)。疼痛控制效果优异，术后6 h NRS评分中位数为3.00(2.00, 3.75)分，术后24 h降至1.00(0.00, 1.00)分，无需额外追加镇痛药物。研究期间无严重不良事件及并发症发生。

国产SR-ENS-600单孔腹腔镜手术机器人系统联合ERAS方案治疗妇科良性疾病安全有效，临床效果不劣于进口同类机器人系统，且在康复效率与成本效益方面更具竞争力，具备良好的临床应用与推广价值。

To evaluate the clinical efficacy and safety of the domestic SR-ENS-600 single-port laparoendoscopic surgical robot system combined with the enhanced recovery after surgery (ERAS) protocol in the treatment of benign gynecological diseases such as ovarian cysts, uterine fibroids, and cervical intraepithelial neoplasia.

A single-arm study was conducted, enrolling 44 patients with benign gynecological diseases who underwent surgery at the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital from Jan. 2023 to Oct. 2025. All patients underwent single-port laparoscopic surgery (including single-port robotic ovarian cystectomy/adnexectomy, myomectomy, and total hysterectomy) using the SR-ENS-600 system, with standardized perioperative ERAS management. The surgical success rate, multiple perioperative parameters (operative time, intraoperative blood loss, time to first flatus, postoperative hospital stay), numerical rating scale (NRS) pain scores, and adverse events were recorded and compared with literature data of the da Vinci SP single-port surgical robot system.

The surgical success rate was100% with no conversion to laparotomy or multi-port laparoscopic surgery. The operative time and intraoperative blood loss in the single-port robotic ovarian cystectomy/adnexectomy (SRC) group, single-port robotic myomectomy (SRM) group, and the overall cohort were lower than those reported for the corresponding procedures with the da Vinci SP system. For the single-port robotic total hysterectomy (SRH) group, the operative time and blood loss were slightly higher than those of the da Vinci SP system, but the difference was not statistically significant. For all patients, the mean time to first flatus was 20.97±6.23 h, and the mean postoperative hospital stay was 2.86±1.66 d, both significantly shorter than those of the da Vinci SP system (34.1±15.5 h and 4.6±0.7 d, respectively). Pain control was excellent: the median NRS pain score was 3.00 (2.00, 3.75) at 6 h postoperatively and decreased to 1.00 (0.00, 1.00) at 24 h postoperatively, with no need for additional analgesic drugs. During the study period, there were no serious adverse events or complications.

The domestic SR-ENS-600 single-port laparoendoscopic surgical robot system combined with the ERAS protocol is safe and effective in the treatment of benign gynecological diseases, comparable to that of imported similar robotic systems, and it is more competitive in terms of recovery efficiency and cost-effectiveness, showing promising potential for clinical application and promotion.